That’s true Hb, although wouldn’t we prefer any takeover tooccur later this year when the company’s likely to have more indications in PhaseII trials?
To quote the End of Year Newsletter:
“…currently in active, confidential discussions withpotential strategic partners in multiple indications and geographies. We lookforward to adding to our portfolio of clinical studies and strategic partners.”
DYOR, GLTAH
Takeover in 2019? Price?, page-109
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.20M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 71590 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 323 | 1 |
View Market Depth
| Last trade - 13.07pm 28/08/2024 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable